Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin for Chronic Pelvic Pain in Women
NCT07818577Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Oct 2026
- Primary completion
- Jun 2027
01
Overview
Randomised, open-label trial of pregabalin in chronic pelvic pain (CPP) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Change in Mean Pain Intensity at 12 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
pregabalin
03
Conditions
chronic pelvic pain (CPP)
Beyond the preview
Go deeper on NCT07818577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818577.